Jessica L. Brady

Jessica L. Brady

Auto-generated profile, based on publicly available information

Jessica L. Brady

Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in Blood
Verified
Journal Article
Closed access
PDF file
MBMichael S. Binkley
Michael S. Binkley
MRM. Shahzad Rauf
M. Shahzad Rauf
SMSarah A. Milgrom
Sarah A. Milgrom
CPChelsea C. Pinnix
Chelsea C. Pinnix
RTRichard W Tsang
Richard W Tsang
RHRichard T. Hoppe
Richard T. Hoppe
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment for stage I-II NLPHL is undefined. We conducted a multi­center retrospective study including patients ≥16 years with stage I-II NLPHL diagnosed from 1995­2018 receiving all forms of management including radiotherapy (RT), combined modality therapy (CMT=RT+chemotherapy), chemotherapy (CT), observation after excision, rituximab and RT, and single agent rituximab (R). End points were progression­free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age 39 years, 72.3% being male, and 54.9% having stage I disease. Median follow up was 5.5 years (IQR=3.1-10.1). 5-year PFS and OS for the entire cohort were 87.1% (95%CI=83.6-90.0%) and 98.3% (95%CI=96.4-99.2%), respectively. Primary management was RT alone (n=257, 46.0%), CMT (n=184, 32.9%), CT alone (n=47, 8.4%), observation (n=37, 6.6%), rituximab and RT (n=19, 3.4%), and rituximab alone (n=15, 2.7%). 5-year PFS rates were 91.1% (95%CI=85.3-94.7%) after RT, 90.5% (95%CI=84.8-94.1%) after CMT, 77.8% (95%CI=61.3-88.0%) after chemotherapy, 73.5% (95%CI=50.6-87.0%) after observation, 80.8% (95%CI=41.0-95.1%) after rituximab and RT, and 38.5% (95%CI=14.0-62.8%) after rituximab alone. For the RT cohort but not the CMT cohort, variant immunoarchitectural pattern and number of sites>2 were associated with worse PFS (P2 (P=0.0006). OS for patients with stage I-II NLPHLwas excellent following all managements.

13 November 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
RWRenata Walewska
Renata Walewska
TEToby Eyre
Toby Eyre
SBSally Barrington
Sally Barrington
JBJessica Brady
Jessica Brady
PFPaul Fields
Paul Fields
TCthe BSH Committee
the BSH Committee

1 July 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MBMichael Sargent Binkley
Michael Sargent Binkley
JFJamie E. Flerlage
Jamie E. Flerlage
KSKerry J Savage
Kerry J Savage
SASaad Akhtar
Saad Akhtar
RSRaphael Steiner
Raphael Steiner
KKKara M. Kelly
Kara M. Kelly
PURPOSE: Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS: Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS: We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored for 916 (40.8%). Frontline management included chemotherapy alone (32.4%), combined modality therapy (30.5%), radiotherapy alone (24.0%), observation after excision (4.6%), rituximab alone (4.0%), active surveillance (3.4%), and rituximab and radiotherapy (1.1%). The PFS, OS, transformation, and lymphoma-specific death rates at 10 years were 70.8%, 91.6%, 4.8%, and 3.3%, respectively. On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age ≥45 years, stage III-IV, hemoglobin <10.5 g/dL, and splenic involvement. Increasing LP-IPS was significantly associated with worse PFS (HR, 1.52) and OS (HR, 2.31) and increased risk of lymphoma-specific death (HR, 2.63) and transformation (HR, 1.41). CONCLUSION: In this comprehensive study of all ages of patients with NLPHL, we develop the LP-IPS to identify high-risk patients and inform upcoming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS scores (<2).

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
JBJ.L. Brady
J.L. Brady
HAH. Attallah
H. Attallah
N. George MikhaeelN. George Mikhaeel
N. George Mikhaeel

1 October 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
FRF. Rahman
F. Rahman
JBJ.L. Brady
J.L. Brady
JDJ.T. Dunn
J.T. Dunn
DSDaniel Smith
Daniel Smith
SBS.F. Barrington
S.F. Barrington
GMG. Mikhaeel
G. Mikhaeel
Consolidation radiotherapy (RT) is frequently used in diffuse large b-cell lymphoma (DLBCL) but its exact impact on outcome is still being debated. Our purpose was to assess the impact of consolidation RT in an unselected population treated homogenously and examine whether the impact is related to initial prognosis or response to chemotherapy.

14 April 2026 in Blood Advances
Verified
Journal Article
Open access
JFJamie E Flerlage
Jamie E Flerlage
DEDennis A. Eichenauer
Dennis A. Eichenauer
MFMichael Fuchs
Michael Fuchs
SHSylvia Hartmann
Sylvia Hartmann
HEHans Theodor Eich
Hans Theodor Eich
MBMichael S. Binkley
Michael S. Binkley
We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group (GLOW) retrospective database of 2243 patients with stage I-IV disease diagnosed from 1992-2021 at 38 international institutions. 779 patients were stage IA with median age of 35 years (range=3-89) and median follow-up of 6.1 years. The 6-year PFS and OS were 86.3% and 97.7%, respectively. Outcomes were analyzed for two groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n=99) had a 6-year PFS of 65.5% versus 90.5% for those who received RT (n=53). Patients with unresected disease (n=627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n=31), 89.6% for RT alone (n=325), 76.8% for ABVD alone (n=40), and 94.3% for ABVD+RT (n=130). 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests 1) RT improves the PFS in patients with completely resected disease; 2) Rituximab or ABVD alone do not appear to achieve a durable response; 3) Chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.